Marielle Fares, PharmD

Contributing Writer https://www.cancertherapyadvisor.com

Marielle Fares, PharmD, is a freelance medical writer and pharmacist based in Washington DC. She received her doctorate of Pharmacy (Pharm D) from the Lebanese American University and is a board-certified geriatric pharmacist. Before transitioning to full-time medical writing in 2017, Marielle worked as a pharmacist in chain drugstores and in private healthcare companies. Marielle has written on a wide range of specialties and disease states, including hematology-oncology, autoimmune diseases, cardiovascular, neuromuscular diseases, and pharmacotherapy.

All articles by Marielle Fares, PharmD

Risk for malignancy was increased in patients who underwent 2 or 3 lines of treatment compared with patients who only underwent 1 line of treatment.

Hematologic Cancers

A New Era: Drug Development for Acute Myeloid Leukemia After the Approval of Venetoclax

Marielle Fares, PharmD

September 25, 2019

Although the 7 + 3 regimen has been the standard of care for acute myeloid leukemia for decades, it may be time to reassess its value and utility.

Hematologic Cancers

Using a Risk-Based System to Predict Progression From Asymptomatic Waldenström Macroglobulinemia

Marielle Fares, PharmD

June 27, 2019

The model stratified patients into 3 risk groups based on median time to disease progression.

Patient with walker being helped by health care worker

Hematologic Cancers

Gait Speed Effectively Predicts Clinical Outcomes in Older Patients With Hematologic Cancers

Marielle Fares, PharmD

June 24, 2019

A decrease in gait speed by 0.1 m/s was associated with increases in mortality and utilization of emergency and acute care.

Platelet aggregation and platelet activation were both independently associated with bleeding risk.

Hematologic Cancers

Predicting Bleeding Risk in Acute Myeloid Leukemia With Thrombocytopenia With Platelet Function Tests

Marielle Fares, PharmD

June 21, 2019

Platelet aggregation and platelet activation were both independently associated with bleeding risk.

Breast Cancer

The KATHERINE Trial Changes the Outlook in High-Risk HER2-Positive Breast Cancer

Marielle Fares, PharmD

March 27, 2019

Trastuzumab emtansine reduces the risk of recurrence by 50% in some HER2-positive breast cancers following neoadjuvant chemotherapy.

Lymphoma

Marginal Zone Lymphoma Presentation at Multiple Mucosal Sites May Be Linked to Poorer Outcomes

Marielle Fares, PharmD

March 19, 2019

Poor prognostic factors for patients with EMZL include age greater than 70 years, advanced Ann Arbor stage, and elevated lactate dehydrogenase (LDH)

Both the chemotherapy regimen selected and therapeutic dose intensity used in treatment factor into

Hematologic Cancers

Managing Neutropenic Sepsis in Patients With Cancer

Marielle Fares, PharmD

March 19, 2019

Septic shock is a leading cause of death in chemotherapy-treated patients with neutropenia, and updated guidelines for managing sepsis in this setting were recently published in Annals of Hematology.

Next post in Hematologic Cancers